Home to CSL’s manufacturing site since the 1950s, funding will support the urgent needs of residents and rebuilding and restoration efforts

KING OF PRUSSIA, PA, USA – March 30, 2026 — CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today announced a $100,000 donation to the Emergency Response Fund of Kankakee & Iroquois Counties to support local recovery efforts following a confirmed tornado and hail devastated parts of Illinois and neighboring states earlier this month.

CSL’s manufacturing site has been in Kankakee since 1954 and employs more than 1,200 people. The facility provides scalable and sustainable capabilities to manufacture medicines for patients globally who rely on plasma-derived therapies.

The Emergency Response Fund, a partnership between United Way of Kankakee & Iroquois Counties and the Community Foundation of Kankakee River Valley, provides funding to local nonprofit organizations. CSL’s donation will help ensure resources are available for residents with urgent needs including emergency supplies and temporary support services and long-term recovery efforts to rebuild and restore the community.

“Our hearts are with the families and individuals who were impacted by these devastating storms,” said Jose Campos, Vice President Manufacturing and Kankakee Site Head, CSL. “Kankakee is our home, and we are committed to standing alongside our community as recovery efforts continue.”

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.  Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.  Today, CSL - including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor - provides lifesaving products to patients in more than 100 countries and employs 29,000+ people.  Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.  For inspiring stories about the promise of biotechnology, visit CSL.com/Vita.  For more information about CSL, visit CSL.com.

Media Contacts

Melissa Tanner, CSL Behring                
Mobile: +1 815-953-4557
Email: melissa.tanner@cslbehring.com

Tom Hushen, CSL
Mobile: +1 267.769.6728 Email: thomas.hushen@cslbehring.com